Search results
Showing 251 to 300 of 314 results for breast cancer
Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)
This guideline has been updated and replaced by NICE guideline NG101.
Docetaxel for the adjuvant treatment of early node-positive breast cancer (TA109)
This guideline has been updated and replaced by NICE guideline NG101.
Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)
This evidence summary has been updated and replaced by NICE guideline NG101.
Guidance on the use of vinorelbine for the treatment of advanced breast cancer (TA54)
This guidance has been updated and replaced by NICE guideline CG81.
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (MTG72)
We have moved Medical technologies guidance 72 to become HealthTech guidance 642. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)
This guideline has been updated and replaced by NICE guideline NG101.
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)
This guidance has been updated and replaced by NICE diagnostics guidance 58.
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG58)
We have moved Diagnostics guidance 58 to become HealthTech guidance 719. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence (MIB44)
This advice has been updated and replaced by NICE diagnostics guidance 34.
Interim methods guide for developing service guidance 2014 (PMG8)
This manual provides information additional to that in Developing NICE guidelines: the manual to guide developers on how to approach developing service guidance, and also to inform stakeholders about the steps that NICE will take in developing this guidance
This guideline has been updated and replaced by NICE guideline NG101.
Interventional procedures, IPG268 - Issued: July 2008 --> We have moved interventional procedures guidance 268 to become HealthTech guidance 171. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
In development Reference number: GID-TA11089 Expected publication date: TBC
This guidance has been updated and replaced by NICE technology appraisal guidance 836.
This guidance has been updated and replaced by NICE technology appraisal guidance 687.
This appraisal has been updated and replaced by NICE guideline CG81.
This advice has been updated and replaced by NICE diagnostics guidance 34.
In development Reference number: GID-TA11588 Expected publication date: TBC
In development Reference number: GID-TA11165 Expected publication date: TBC
This guidance has been updated and replaced by NICE technology appraisal guidance 1040.
In development Reference number: GID-TA11273 Expected publication date: TBC
We have moved Diagnostics guidance 8 to become HealthTech guidance 315. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This guidance has been updated and replaced by NICE technology appraisal guidance 816.
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
In development Reference number: GID-TA11546 Expected publication date: TBC
This guidance has been updated and replaced by NICE technology appraisal guidance TA421.
In development Reference number: GID-TA11771 Expected publication date: TBC
This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.
Discontinued Reference number: GID-TA11339
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.
This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE
Thousands more breast cancer patients to benefit from new NHS treatment
NICE approves ribociclib combination therapy to help prevent cancer returning in early-stage disease.
Thousands of people a year could benefit from new twice-a-day tablet for advanced breast cancer
We've published final draft guidance recommending capivasertib with fulvestrant, which means the treatment will be funded immediately through the Cancer Drugs Fund.
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018.
NICE recommends Enhertu for more people with advanced breast cancer
Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage disease, in final draft guidance.
Draft guidance for the potential of new targeted treatment for type of advanced breast cancer
NICE has today (26 September 2023) published draft guidance for public consultation that does not recommend trastuzumab deruxtecan for treating advanced HER2-low breast cancer in adults.
New treatment for advanced breast cancer recommended by NICE
Around 300 people are set to benefit following NICE’s recommendation of talazoparib for treating a type of locally advanced or metastatic breast cancer in final draft guidance published today (19 January 2024).
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
NICE has issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.
NICE recommends innovative technology for people with breast cancer
A magnetic marker liquid injected into people with invasive breast cancer will help surgeons discover if the cancer has spread.
NICE approves routine use of drug combination for advanced breast cancer
A life-extending drug combination for some people with advanced breast cancer will now be available for routine use in the NHS.
Further treatment option for triple-negative breast cancer recommended
NICE has today (8 November 2022) published final draft guidance which recommends pembrolizumab as an option for people with a type of breast cancer called triple-negative breast cancer.
NICE provides access to new treatment option for advanced breast cancer
NICE has today (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF).
Around 400 people with advanced breast cancer are set to benefit from a new treatment
Tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading.
More people could be offered genetic testing for genes linked to ovarian cancer
A new draft NICE guideline for inherited ovarian cancer published today (15 September 2023), recommends more people are tested for genes linked to ovarian cancer.
Today (1 October 2024) NICE is consulting on draft guidance that does not recommend elacestrant for treating a type of advanced breast cancer.
NICE Board says new method allowing greater weight to be given to severe diseases is working
At today's meeting (25th September 2024) our board has concluded that the new severity modifier is working as intended.